Patents by Inventor Thomas C. T. Shum

Thomas C. T. Shum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSION
    Publication number: 20230331819
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 19, 2023
    Inventors: Robert Layne KRUSE, Karl-Dimiter BISSIG, Stephen M.G. GOTTSCHALK, Thomas C.T. Shum
  • Antibody based gene therapy with tissue-directed expression
    Patent number: 11566063
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 31, 2023
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
    Patent number: 11219646
    Abstract: Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 11, 2022
    Assignee: Baylor College of Medicine
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
    Publication number: 20190307798
    Abstract: Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 10, 2019
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSION
    Publication number: 20190225673
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • CONSTITUTIVELY ACTIVE CYTOKINE RECEPTORS FOR CELL THERAPY
    Publication number: 20190183936
    Abstract: Embodiments of the disclosure include methods and compositions for enhancing expansion of immune cells for immunotherapy. In particular embodiments, immune cells, such as T-cells, express a constitutively active cytokine receptor in which the transmembrane and endodomains are able to provide an activating signal separately from any input to the corresponding exodomain to which they are operably linked. In specific embodiments, the transmembrane and endodomain from IL-7R? is utilized with the exodomain of CD34.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 20, 2019
    Inventors: Thomas C. T. Shum, Shum, Stephen M. G. Gottschalk, Bilal Omer, Cliona M. Rooney